Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5589 ARTÍCULOS , VIENDO DEL 1906 AL 1920

The subthalamic nucleus and the placebo effect in Parkinson's disease

Frisaldi E, Zamfira DA, Benedetti F.

Handb Clin Neurol. 2021;180:433-444. doi: 10.1016/B978-0-12-820107-7.00027-6.

Spatial topography of the basal forebrain cholinergic projections: Organization and vulnerability to degeneration

Schmitz TW, Zaborszky L.

Handb Clin Neurol. 2021;179:159-173. doi: 10.1016/B978-0-12-819975-6.00008-X.

The diagonal band of Broca in health and disease

Liu AKL, Gentleman SM.

Handb Clin Neurol. 2021;179:175-187. doi: 10.1016/B978-0-12-819975-6.00009-1.

Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease

Wilson H, de Natale ER, Politis M.

Handb Clin Neurol. 2021;179:189-205. doi: 10.1016/B978-0-12-819975-6.00010-8.

The circadian system in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Fifel K, De Boer T.

Handb Clin Neurol. 2021;179:301-313. doi: 10.1016/B978-0-12-819975-6.00019-4.

A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease

Fevga C, Park Y, Lohmann E, Kievit AJ, Breedveld GJ, Ferraro F, de Boer L, van Minkelen R, Hanagasi H, Boon A, Wang W, Petsko GA, Hoang QQ, Emre M, Bonifati V.

Parkinsonism Relat Disord. 2021 Aug;89:63-72. doi: 10.1016/j.parkreldis.2021.06.023. Epub 2021 Jun 29.

Catatonia as the Initial Manifestation of Dementia with Lewy Bodies

Saito Y, Noto K, Kobayashi R, Suzuki A, Morioka D, Hayashi H, Otani K.

Am J Case Rep. 2021 Jul 7;22:e932018. doi: 10.12659/AJCR.932018.

Deciphering the detailed structure-activity relationship of coumarins as Monoamine oxidase enzyme inhibitors-An updated review

Koyiparambath VP, Prayaga Rajappan K, Rangarajan TM, Al-Sehemi AG, Pannipara M, Bhaskar V, Nair AS, Sudevan ST, Kumar S, Mathew B.

Chem Biol Drug Des. 2021 Oct;98(4):655-673. doi: 10.1111/cbdd.13919. Epub 2021 Jul 26.

The mystery of claustral neural circuits and recent updates on its role in neurodegenerative pathology

Nikolenko VN, Rizaeva NA, Beeraka NM, Oganesyan MV, Kudryashova VA, Dubovets AA, Borminskaya ID, Bulygin KV, Sinelnikov MY, Aliev G.

Behav Brain Funct. 2021 Jul 7;17(1):8. doi: 10.1186/s12993-021-00181-1.

[The Relationship Between Pathophysiology and Neurotransmitters in Parkinson's Disease]

Takeda A, Tomiyama M, Hanajima R.

Brain Nerve. 2021 Jul;73(7):829-837. doi: 10.11477/mf.1416201843.

PIAS2-mediated blockade of IFN-β signaling: a basis for sporadic Parkinson disease dementia

Magalhaes J, Tresse E, Ejlerskov P, Hu E, Liu Y, Marin A, Montalant A, Satriano L, Rundsten CF, Carlsen EMM, Rydbirk R, Sharifi-Zarchi A, Andersen JB, Aznar S, Brudek T, Khodosevich K, Prinz M, Perrier JM, Sharma M, Gasser T, Issazadeh-Navikas S.

Mol Psychiatry. 2021 Oct;26(10):6083-6099. doi: 10.1038/s41380-021-01207-w. Epub 2021 Jul 8.

FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics

Liu Y, Deng J, Liu Y, Li W, Nie X.

Front Pharmacol. 2021 Jun 21;12:675725. doi: 10.3389/fphar.2021.675725. eCollection 2021.

Nutritional Ketosis in Parkinson's Disease - a Review of Remaining Questions and Insights

Choi A, Hallett M, Ehrlich D.

Neurotherapeutics. 2021 Jul;18(3):1637-1649. doi: 10.1007/s13311-021-01067-w. Epub 2021 Jul 7.

Changing Gears - DBS For Dopaminergic Desensitization in Parkinson's Disease?

Weiss D, Volkmann J, Fasano A, Kühn A, Krack P, Deuschl G.

Ann Neurol. 2021 Nov;90(5):699-710. doi: 10.1002/ana.26164. Epub 2021 Jul 20.

Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial

Freire-Alvarez E, Kurča E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, Sánchez-Soliño O, Barbato LM.

Mov Disord. 2021 Nov;36(11):2615-2623. doi: 10.1002/mds.28703. Epub 2021 Jul 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias